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Purpose: To examine the feasibility of volumetric modulated arc therapy (VMAT) for post mastectomy
radiotherapy (PMRT).
Methods and materials: Fifteen PMRT patients previously treated at our clinic with helical tomotherapy (HT)
were identified for the study. Planning target volumes (PTV) included the chest wall and regional lymph nodes.
A systematic approach to constructing VMAT that met the clinical goals was devised. VMAT plans were then
constructed for each patient and compared with HT plans with which they had been treated. The resulting plans
were compared on the basis of PTV coverage; dose homogeneity index (DHI) and conformity index (CI); dose to
organs at risk (OAR); tumor control probability (TCP), normal tissue complication probability (NTCP) and secondary
cancer complication probability (SCCP); and treatment delivery time. Differences were tested for significance using
the paired Student’s t-test.
Results: Both modalities produced clinically acceptable PMRT plans. VMAT plans showed better CI (p < 0.01) and
better OAR sparing at low doses than HT plans, particularly at doses less than 5 Gy. On the other hand, HT plans
showed better DHI (p < 0.01) and showed better OAR sparing at higher doses. Both modalities achieved nearly
100% tumor control probability and approximately 1% NTCP in the lungs and heart. VMAT showed lower SCCP
than HT (p < 0.01), though both plans showed higher SCCP values than conventional mixed beam (electron-photon)
plans reported by our group previously. VMAT plans required 66.2% less time to deliver than HT.
Conclusions: Both VMAT and HT provide acceptable treatment plans for PMRT. Both techniques are currently utilized
at our institution.
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Post-mastectomy radiotherapy (PMRT) presents a chal-
lenging treatment geometry. The target volume - typically
consisting of the chest wall (CW) and regional lymph
nodes - covers a large, superficial area that is thin and
convex in shape, and is immediately adjacent to the
lung, heart, and contralateral breast. A variety of tech-
niques have been proposed for PMRT. In our clinic,
PMRT was historically treated with a mixed-beam tech-
nique consisting of anterior electrons to treat the medial
CW and internal mammary nodes (IMN), oblique elec-
trons to treat the lateral CW, and parallel-opposed x-ray
to treat the supraclavicular (SC) and axillary (AX) nodes.* Correspondence: jfontenot@marybird.com
1Department of Physics and Astronomy, Louisiana State University and
Agricultural & Mechanical College, Baton Rouge, LA, USA
2Mary Bird Perkins Cancer Center, Baton Rouge, LA 70809, USA
© 2014 Nichols et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Because of the need to junction fields, edge feathering
was typically utilized to reduce heterogeneities to ac-
ceptable levels; however, residual heterogeneities were
inevitable and treatment setup times were lengthy and
laborious. Subsequently, our group previously reported
on the use of helical tomotherapy (HT) for PMRT [1]
to improve ease of setup and dose conformity and ho-
mogeneity of PMRT treatments, albeit at the cost of larger
volumes of normal tissue receiving doses less than 25 Gy.
Nonetheless, our previous findings resulted in HT often
being the treatment of choice for PMRT in our clinic.
However, the use of HT has limitations, including limited
availability of and access to the technology in addition to
the larger low dose volumes noted above.
Volumetric modulated arc therapy (VMAT) is a rota-
tional IMRT delivery technique that is widely availableLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Dosimetric planning goals for the PMRT patients
in this study
Structure Dose Volume
PTV < 55 Gy 1%
50.4 Gy 90%
> 46 Gy 99%
Lungs < 20 Gy 18%
Heart < 20 Gy 18%
Breast < 5 Gy 1%
Liver < 15 Gy 15%
Airway < 30 Gy 1%
Esophagus < 30 Gy 1%
Cord < 25 Gy 1%
Normal Tissue < 55 Gy 1%
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been shown to provide dose distributions comparable to
fixed-beam IMRT while improving treatment efficiency
for a variety of cases [2-5], including PMRT [6,7].
However, for PMRT, those studies compared VMAT
with conventional 3D conformal techniques only and, in
particular, there are currently no known studies that
have compared VMAT with HT for PMRT. Since studies
comparing VMAT and HT for other sites have produced
mixed results [2,8,9], it was unknown if VMAT could
complement HT as a competitive alternative in our PMRT
program.
The objectives of this study were to (1) devise a sys-
tematic method of constructing VMAT plans to meet
our clinical goals, similar to our previous approach with
HT and (2) compare VMAT planning results with HT
plans for patients previously treated for PMRT in our
clinic. VMAT plans were constructed for 15 PMRT pa-
tients previously treated with HT. The resulting plans
were compared based on dosimetric quality, radiobio-
logical calculations and delivery efficiency.
Methods and materials
Patients
A power analysis of data from previous studies (8, 9) in-
dicated a required study size of fifteen patients, who
were randomly selected from a list of PMRT patients
previously treated with HT in our clinic: 7 requiring ir-
radiation of the right CW, 8 requiring irradiation of the
left CW. 11 patients in the study underwent unilateral
mastectomy on the side of irradiation, with the remai-
ning 4 having bilateral mastectomy (though those pa-
tients were only irradiated on one side). Each patient’s
CT data set was anonymized and placed in database
compliant with the Health Insurance Portability and
Accountability Act. Research ethics was obtained from
the institutional research policy committee. The average
age of the patient cohort was 60.5 years (range: 30 to
85 years).
Simulation, contouring, and planning goals
All patients underwent three-dimensional treatment si-
mulation in the supine position with a custom 1-cm
thick solid thermoplastic bolus (Aquaplast RT®, Radi-
ation Products Design, Inc., Albertville, MN) added to
the CW daily to increase the skin dose and to assist in
creating flash during treatment planning. The planning
target volume was delineated by a radiation oncologist,
and included the CW (including bolus) and relevant
nodal regions (IMN, AX, and SCV). Delineated organs
at risk (OAR) included the lungs, heart, contralateral
breast, esophagus, and spinal cord.
The prescription dose for all patients was 50.4 Gy in
28 fractions. Dosimetric planning goals (see Table 1) weredetermined from normal tissue tolerances by Emami et al.
[10] and from the clinical experience of radiation oncolo-
gists at our clinic.
Due to the potentially subjective nature of treatment
planning, extreme care was taken to develop a system-
atic and rigorous procedure for producing the optimum
plan for each patient and modality. The planning vari-
ables for each delivery approach were carefully investi-
gated and their impact on plan quality was documented.
The approaches to producing HT and VMAT treatment
plans for each patient are described below.
Helical tomotherapy planning
HT treatment plans were created using the TomoTherapy
treatment planning system (version 3.1.2) with treatment
values typical of clinical delivery in our clinic, including a
nominal jaw width of 5 cm, a pitch of 0.287, and a “nor-
mal” grid size. HT plans were optimized with a maximum
modulation factor of 3.0 in “beamlet” mode, which per-
forms an initial full dose calculation to determine the con-
tribution of dose from every possible leaf opening, then
optimizes leaf open times to minimize the optimization
objective function. Initial optimization objectives were set
to achieve the planning goals, but adjusted during op-
timization to produce the best plan for each patient using
a systematic procedure described in detail elsewhere [11].
A minimum of 250 total optimization iterations were
completed until planning objectives were met or until the
plan could no longer be improved.
Volumetric modulated arc therapy planning
VMAT treatment plans were created using the Philips
Pinnacle treatment planning system (version 9.0, Philips
Medical Systems, Fitchburg, WI). All VMAT treatment
plans were constructed for an Elekta Infinity radiother-
apy system (Elekta AB, Stockholm, Sweden) using 6 MV
photons. All patients were planned using a couch angle
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of 220° each were utilized, with the start and stop angles
of the first arc set to 50° and 190° (IEC convention, rotat-
ing counterclockwise), respectively, for right CW patients
and 170° and 310° (rotating clockwise), respectively, for
left CW patients. These angles were chosen to avoid direct
irradiation of the spinal cord, contralateral breast and
contralateral lung during irradiation. The dose grid was
set to the default value of 4 × 4 × 4 mm3. Optimization
was performed using the SmartArc module using a 4 de-
gree final gantry spacing, a leaf motion constraint of
4 mm per degree of arc rotation, and a maximum delivery
time of 60 seconds per 220° partial arc. Initial optimization
objectives were set to achieve the planning goals, but
adjusted during optimization using a systematic proce-
dure found to produce optimal plan quality. Additional
details of the VMAT planning procedure can be found
elsewhere [11].
Plan comparison metrics
HT and VMAT plans were compared on the basis of
dosimetric end points, radiobiological calculations, and
delivery efficiency. The following quantities were com-
pared: target coverage (D95%), dose homogeneity, con-
formity, and tumor control probability (TCP) for the
PTV; irradiated volumes, normal tissue complication
probability (NTCP), and secondary cancer complication
probability (SCCP) for the normal tissues.
In the PTV, the dose homogeneity was compared
using the dose homogeneity index (DHI), calculated as
DHI ¼ Dmax−Dmin
DRx
where Dmax, Dmin, and DRx denote the maximum, mini-
mum, and prescription doses, respectively. Values of DHI
are unitless, with smaller values representing more uni-
form doses. Dose conformity was compared using the





where TV is the target volume, PIV is the volume of the
prescribed isodose value and TVPIV is the volume of the
target that is covered by the prescribed isodose value.
Values of CI are unitless, with larger values representing
better dose conformity. Finally, TCP was calculated
using a linear quadratic model for survival fraction with
a repair mechanism correction [12]. Values for breast
cancer taken from Wigg [13] were α (=0.51 Gy-1), β
(=0.061 Gy-2), repair time (=1 h), and clonogenic cell
density (107 cm-3).
Doses to the normal tissues were evaluated using frac-
tional volumes consistent with the planning goals andrelevant clinical end points. The percent volume of the
lungs and heart receiving greater than 20 Gy (V20Gy) and
15 Gy (V15Gy), respectively, were compared. The mean
dose to the contralateral breast was also evaluated.
Normal tissue complication probabilities (NTCP) for
radiation-induced pneumonitis were computed for the
lung using the Lyman-Kutcher-Berman probit model
[14-16] using the following values: D50 = 24.5 Gy (10),
n = 0.87, and m = 0.18 (16). NTCP for radiation-induced
ischema for the heart was calculated using the relative
seriality model [17] using the following values: D50 =
52.3 Gy, s = 1.0, and γ = 1.28 [18].
The organ equivalent dose (OED) formalism of Schneider
[19,20] was used to compute secondary cancer compli-
cation probability (SCCP) for the lungs (α = 0.085 Gy-1,
Inorg = 1.68% Gy
-1), contralateral breast (α = 0.085 Gy-1,
Inorg = 0.78% Gy
-1), and normal tissue (excludes delineated
PTV and OARs; α = 0.085 Gy-1, Inorg = 1.76% Gy
-1). Inorg
was estimated using atomic bomb survivor data and
applies to whole-body irradiation. Because the CT sets for
these patients were limited to partial body scans, the
SCCP for normal tissue was reduced by the ratio of the
volume of normal tissue to the volume of an average
woman, calculated using the average weight, 74.7 kg, of
women between the ages of 20 and 74 [21], and an
estimated average density of 0.001 kg/cm3.
Delivery efficiency was evaluated by comparing the ac-
tual treatment delivery time for each plan. The delivery
time of each VMAT plan was measured using a stop-
watch. HT delivery times were taken from the planning
system report, which contains an accurate estimate of
delivery time for each patient.
All values (dosimetric, radiobiological, and delivery)
from the fifteen patients were averaged and compared.
Differences were evaluated for statistical significance (p <
0.05) using the Student’s paired t-test.
Results
Isodose distributions and dose-volume histograms for a
representative patient are shown in Figures 1 and 2, re-
spectively. The figure shown compares a VMAT and HT
plan in the axial and coronal planes. The VMAT plan
contained larger contiguous regions of 105% of the pre-
scription dose within the PTV compared with the HT
plan, indicating better homogeneity with HT (DHI =
0.161 and 0.085 for VMAT and HT, respectively). Com-
parable PTV coverage was noted between the plans, with
HT failing to cover the edge of the PTV near the medial
aspect of the lung. The VMAT plan showed better dose
conformity (CI = 0.773 and 0.700 for VMAT and HT, re-
spectively), with the HT plan consistently showing pre-
scription doses in normal tissue located lateroposterior
to the PTV. Lower isodose lines (i.e., 25, 15, and 5 Gy)
also extended further into normal tissue in the HT plan.
Figure 1 Comparison of VMAT and HT treatment plans. Transverse and coronal isodose distributions for the VMAT (a, b) and HT plans
(c, d) are shown. Isodose contours are 55, 52.9 (105%), 50.4, 45.3 (90%), 35, 25, 15, and 5 Gy.
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plans with for a variety of dosimetric and radiobiological
metrics. Values are presented as means for the fifteen
patients. In general, differences between the delivery ap-
proaches were small but statistically significant, indica-
ting a consistent advantage (or disadvantage) in each
technique across the patient cohort. These trends are
discussed in more detail below.Figure 2 Comparison of VMAT and HT treatment plans. Dose-volumePlanning target volume
Both VMAT and HT provided clinically acceptable doses
to the PTV, though significant (p < 0.05) differences were
noted between the plans. For example, HT plans consist-
ently showed slightly better coverage (DV95%
— ¼ 49:8 Gy
vs. 49.3 Gy, p < 0.001) and better dose homogeneity
(DHI
— ¼ 0:096 vs. 0.147, p < 0.001) in PTV. On the other
hand, VMAT showed better dose conformity (CI
— ¼ 0:778histograms for the distributions shown in Figure 1.
Table 2 Summary comparison of VMAT and HT plans
Structure/Item Metric VMAT HT p-value
PTV DV95% (Gy) 49.3 ± 0.1 49.8 ± 0.1 <0.001
DHI 0.147 ± 0.009 0.096 ± 0.005 <0.001
CI 0.778 ± 0.008 0.719 ± 0.008 <0.001
TCP 99.8 ± 0.2 100 ± 0.0 0.002
Total lung V5Gy (%) 66.2 ± 3.1 89.8 ± 1.4 <0.001
V20Gy (%) 16.3 ± 0.2 15.0 ± 0.3 <0.001
NTCP (%) 0.3 ± 0.1 0.6 ± 0.1 0.06
SCCP (%) 5.3 ± 0.1 6.1 ± 0.0** <0.001
Ipsilateral lung V5Gy (%) 96.9 ± 1.3 99.3 ± 0.5 0.06
V20Gy (%) 32.3 ± 0.8 29.9 ± 1.0 <0.001
Contralateral lung V5Gy (%) 37.8 ± 4.9 81.7 ± 2.5 <0.001
Heart* V15Gy (%) 26.0 ± 1.9 28.2 ± 2.6 0.4
Dmean (Gy) 12.9 ± 0.5 14.4 ± 0.6 0.04
Dmax (Gy) 42.2 ± 1.6 38.3 ± 1.3 <0.001
NTCP (%) 1.3 ± 0.2 0.9 ± 0.1 0.008
Contralateral breast Mean dose (Gy) 1.5 ± 0.1 1.8 ± 0.1 <0.001
SCCP (%) 1.0 ± 0.0** 1.2 ± 0.0** <0.001
Non-specific normal tissue Mean dose (Gy) 7.0 ± 0.2 11.1 ± 0.4 <0.001
SCCP (%) 0.7 ± 0.0 0.9 ± 0.0** <0.001
Efficiency Delivery time (s) 128.6 ± 2.8 382.4 ± 10.9 <0.001
Values shown are averages of the 15 patients (± 1σ) with the exception of the heart.
*Patients with right-side mastectomy excluded.
**Standard deviation of the mean < 0.05.
Abbreviations: PTV planning target volume, DHI dose homogeneity index (ideal = 0), CI conformity index (ideal = 1), TCP tumor control probability, NTCP normal
tissue complication probability, SCCP secondary cancer complication probability.
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dose spill beyond the posterior region of the PTV in HT
plans. For radiobiological calculations, both modalities
achieved nearly 100% TCP.
The quality of the high region of dose distribution of
VMAT plans was influenced by whether the patient
underwent unilateral or bilateral mastectomy despite theTable 3 Summary of VMAT and HT plans comparing patients
Modality Metric Unilateral mastect
VMAT DV95% (Gy) 49.2 ± 0.1
DHI 0.161 ± 0.006
CI 0.766 ± 0.007
TCP (%) 99.8 ± 0.0*
HT DV95% (Gy) 49.8 ± 0.1
DHI 0.101 ± 0.007
CI 0.715 ± 0.010
TCP (%) 100.0 ± 0.0
Values shown are averages of the 15 patients (± 1σ) with the exception of the hear
*Standard deviation of the mean < 0.05.
Abbreviations: TCP tumor control probability, DHI dose homogeneity index (ideal = 0fact that all patients underwent radiotherapy planning
for unilateral irradiation. Table 3 shows PTV metrics for
VMAT and HT plans for each subpopulation. VMAT
dose distributions were significantly more homogeneous
(p < 0.05) and conformal in patients who underwent bi-
lateral mastectomy compared with those who did not.
Such differences were not observed in HT plans, norwho underwent unilateral and bilateral mastectomy
omy Bilateral mastectomy p-value
49.6 ± 0.1 <0.001
0.106 ± 0.014 0.001
0.811 ± 0.012 0.004
99.8 ± 0.1 0.4
50.0 ± 0.1 0.4
0.082 ± 0.004 0.1
0.731 ± 0.013 0.4
100.0 ± 0.0 1.0
t.
), CI conformity index (ideal = 1).
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ther modality between the two subpopulations.
Normal tissues
Both VMAT and HT also produced clinically acceptable
normal tissue doses. In general, differences were small
but significant (p < 0.05) with VMAT showing better
dose sparing at low dose intervals (e.g., < 15 Gy) and HT
showing better dose sparing at higher doses. In the lung,
V5Gy was approximately 25% lower (p < 0.001) in VMAT
plans, while V20Gy was approximately 9% lower (p < 0.001)
in HT plans. The NTCP for post-radiation pneumonitis
was lower in VMAT plans, but was not significant (p =
0.06). The SCCP in the lung from VMAT plans was 5.3 ±
0.1% compared with 6.1 ± 0.0% from HT plans (p < 0.001).
In the heart, differences in V15Gy and V30Gy were small
and not statistically significant. However, because VMAT,
on average, showed a larger V30Gy, the NTCP for ischemia
was higher in VMAT plans (p = 0.008). In the contralateral
breast, differences in the mean dose and SCCP were small
but were statistically significant (p < 0.001) in favor of
VMAT plans. Finally, VMAT showed a slightly lower
mean dose and SCCP compared with HT (p < 0.001),
though values of SCCP were less than 1%.
Delivery efficiency
Delivery time measurements showed that VMAT plans
were delivered significantly faster at 128.6 ± 2.8 seconds,
compared with 382.4 ± 10.9 seconds (p < 0.001) for HT
plans. Delivery of all planned treatments was confirmed
via quality assurance measurements using a two di-
mension diode array (MapCHECK2, Sun Nuclear Corp.,
Melbourne, FL USA), with all plans showing better than
90% of measured dose points within 3% dose difference or
3 mm distance to agreement of planned dose points.
Discussion
VMAT and HT plans were clinically comparable for
PMRT, with VMAT plans needing approximately 66%
less time to deliver. HT plans showed significantly bet-
ter dose homogeneity and sparing of normal tissues at
dose intervals greater than approximately 15 Gy. On the
other hand VMAT plans showed significantly better
dose conformity and better sparing of normal tissues at
dose intervals less than approximately 10 Gy.
While HT plans showed better dose homogeneity, dif-
ferences between HT and VMAT plans were smaller in
patients who underwent bilateral mastectomy owing to
improved dose homogeneity (and conformity) of VMAT
plans in that subpopulation. The reason for this is that
the contralateral intact breast presented as a difficult
avoidance structure during volumetric optimization of
PMRT plans, typically showing the greatest objective value
of all normal tissue constraints. This suggests that planquality can be improved in PMRT patients for whom con-
tralateral breast dose is of less concern (e.g., bilateral mas-
tectomy, patients with advanced age, etc.). In contrast, HT
plans - which can be more highly modulated at each he-
lical slice of delivery - did not show this effect.
Differences in radiobiological calculations were small
but statistically significant across modalities. Both plans
showed nearly 100% tumor control. In normal tissue, both
plans predicted only slight risk of lung and cardiac to-
xicities, with VMAT showing a small advantage for the
former and HT showing a small advantage for the latter.
HT showed values of SCCP that were significantly higher
than that of VMAT plans in the lung (0.9 percentage
points), contralateral breast (0.2), and non-specific normal
tissues (0.2). However, while VMAT plans showed lower
SCCP values in this study, a previous study from our
group showed that SCCP values of HT plans were appro-
ximately twice that of conventional mixed beam (photon-
electron) plans in PMRT patients [1] and, therefore,
VMAT plans should show similarly elevated SCCP values
if compared with mixed beam plans. It should also be
noted that the radiobiological model coefficients have
considerable uncertainty, and that absolute values of risk,
while small, should be interpreted with caution.
Treatment planning results from this study are com-
parable to other studies that have investigated HT and
VMAT for locoregional irradiation for breast cancer,
though none to our knowledge have reported use of the
5 cm jaw width for HT or the specific case of post-
mastectomy irradiation for VMAT. For VMAT, Popescu
et al. [22] reported PTV coverage and homogeneity val-
ues for node-positive breast patients that are similar to
the present study. OAR sparing was similar for the lung
(V20Gy = 16.3% vs. 16.9%) but slightly better for the heart
in their study (Dmean of 12.9 Gy vs. 10.9 Gy), which may
be attributable to a lower prescription dose of 45 Gy
to internal mammary nodes. For HT, a previous study
from our institution showed acceptable dosimetric re-
sults from HT plans using a 2.5 cm nominal jaw width
for PMRT planning; however, due to the large treatment
area, treatment delivery times exceeded 20 minutes [1],
which is consistent with a previous study from Hijal
et al. [23]. Because of this, use of the 5 cm jaw for PMRT
in our clinic has significantly reduced treatment delivery
time to about 6 minutes with corresponding degradation
of plan quality, primarily in the dose-falloff region be-
tween the PTV and OARs (i.e., heart and ipsilateral lung).
Despite the change, OAR doses were still within accept-
able limits and determined to be worth the substantial re-
duction in treatment delivery time. With respect to the
current study, use of the 2.5 cm jaw would likely have only
served to widen the observed dosimetric advantage of HT
in the lung, with some additional gains in cardiac sparing,
again at the expense of marked increase in delivery time.
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VMAT plans would likely not be affected since difference
in these dose-volumes between our previous (using the
2.5 cm jaw) and current (using the 5 cm jaw) studies are
negligible.
One limitation of the study was that only one dose-
volume objective (e.g., V20Gy < 20%) could be specified
for a given organ at risk in the TomoTherapy planning
system. As a result, it was not feasible to include lower
dose objectives to control the low dose spill through-
out the irradiated volume of each patient during optimi-
zation. However, the latest version of the TomoTherapy
planning system now offers the user the ability to input
multiple dose-volume objectives for organs at risk, and
it is possible that the low dose volume in HT plans
could have been reduced had that feature been available
at the time of the study. To examine the influence of this
feature, optimization of a HT plan for a PMRT patient
was performed with and without an objective of V5Gy <
70% in the lungs using the same optimization procedure
previously described. The value of V5Gy was found to de-
crease from 93.4% to 85.5% when using utilizing the
V5Gy objective; however, dose to other structures corres-
pondingly increased (for example, V15Gy in the heart in-
creased from 19.8% to 22.5%). Thus, we estimate that
the use of low dose objectives during HT planning may
slightly reduce the low dose volume, but would be un-
likely to change the conclusions of this study given the
wide margin by which VMAT plans reduced low dose
volumes compared with HT (average lung V5Gy of 66.2%
vs. 89.8%).
Finally, delivering an adequate dose to the skin is cri-
tical during PMRT, as there is the substantial risk of
recurrence in the chest wall [24]. Even with the use of
thermoplastic bolus, substantial portions of the target
volume are within 2 cm of the surface, and accurate dose
calculation is challenging in this area, particularly with
rotational delivery schemes. Using thermoluminescent
dosimeters, our group previously reported on in vivo
dose verification of skin doses from HT plans for PMRT
as calculated by the TomoTherapy planning system [25].
For VMAT, the accuracy of superficial doses calculated by
the Pinnacle treatment planning system has been docu-
mented for IMRT in other sites [26]. While preliminary
in vivo verification measurements of skin doses from
VMAT for PMRT patients in our clinic have shown simi-
larly good agreement, future work may include a clini-
cal protocol for systematic evaluation of in vivo doses
from VMAT plans for PMRT, similar to our previous
report on HT. Additional future studies may also in-
clude investigation of methods that reduce low dose
spill of both VMAT and HT plans or the use of fixed-field
IMRT in cases where neither VMAT nor HT are clinically
available.Conclusions
VMAT is capable of producing treatment plans for PMRT
that are dosimetrically and radiobiologically comparable
to HT and can be delivered in approximately 66% less
time. Currently, both modalities are used to treat PMRT at
our clinic.
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